Compare CF Industries Holdings, Inc. (CF) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CF Industries Holdings, Inc. vs Novartis AG — how do they compare? CF Industries Holdings, Inc. trades at $117.99 (market cap $18.31B), while Novartis AG trades at $150.72 (market cap $288.65B). The key difference: Novartis AG is far larger — about 15.8× CF Industries Holdings, Inc.'s market cap, and Novartis AG pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| CF | NVS | |
|---|---|---|
Market Cap | $18.31B | $288.65B |
Sector | Basic Materials | Health |
52-Week High | $137.55 | $168.62 |
52-Week Low | $76.08 | $113.50 |
Enterprise Value | $19.89B | $328.67B |
Dividend Yield | 2.01% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CF Industries stock trades at $120.92, up 3.42% today, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a 20% dividend hike announced July 8, 2026, and robust profitability metrics like a 23.73% net margin support investor confidence. The stock is near consensus price targets, with moving averages signaling upward momentum.
The outlook is positive, driven by firm nitrogen demand and shareholder returns, but risks include input cost pressures and cyclical industry headwinds. Upside potential exists if earnings continue to exceed expectations, though overbought RSI levels suggest near-term consolidation may occur.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
